https://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanomaContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanomahttps://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanoma#u48570Wed, 26 Aug 2026 01:50:35 +0000Merck and Moderna's personalized mRNA cancer vaccine, combined with pembrolizumab, has shown significant promise in preventing the recurrence of melanoma in high-risk patients. The vaccine, which targets individual tumors, successfully cleared phase 3 clinical trials. This treatment approach marks a shift towards personalized oncology, tailored to a patient's specific genetic makeup. The results suggest a potential new treatment option for patients at high risk of melanoma recurrence.Why it mattersMelanoma is a serious form of skin cancer that can be life-threatening if not treated p https://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanomahttps://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanoma#u46142Sat, 22 Aug 2026 03:10:48 +0000Moderna and Merck developed a personalized mRNA cancer vaccine that significantly reduces melanoma recurrence when combined with the immunotherapy drug pembrolizumab. The treatment successfully cleared phase 3 clinical trials, which is the final step required before seeking FDA approval. This neoantigen treatment targets individual tumors to prevent skin cancer from returning in patients. The results suggest a shift toward personalized oncology treatments tailored to the specific genetic makeup of a patient's tumor.Why it mattersTraditional cancer treatments often apply a one-size-fits-al https://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanomahttps://www.live-feeds.com/feed/merck-and-moderna-say-cancer-vaccine-shows-promise-in-preventing-recurrence-of-melanoma#u45612Thu, 20 Aug 2026 18:11:40 +0000Moderna and Merck's cancer vaccine has shown promise in preventing the recurrence of melanoma in a late-stage trial. The vaccine, which uses mRNA technology, has been found to be effective in reducing the risk of melanoma recurrence. The trial results have led to a surge in Moderna's stock price.Why it mattersMelanoma is a type of skin cancer that can be deadly if not treated early. Current treatments for melanoma include surgery, chemotherapy, and immunotherapy. The development of a cancer vaccine could provide a new treatment option for patients with melanoma. The vaccine works by